NCT03038672 2025-11-10Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell LymphomasNational Cancer Institute (NCI)Phase 2 Active not recruiting54 enrolled 12 charts